Find Reports
Select Report Type
Reimbursement Review
Displaying 201 - 225 of 1430
Please scroll or swipe to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| berotralstatOpens in new tab | Orladeyo | berotralstat | hereditary angioedema (HAE) | Reimburse with clinical criteria and/or conditions | Complete | SR0723-000 | |||
| lumasiranOpens in new tab | Oxlumo | lumasiran | Primary hyperoxaluria type 1 | Reimburse with clinical criteria and/or conditions | Complete | SR0734-000 | |||
| MelanomaOpens in new tab | Melanoma | Complete | PH0022-000 | ||||||
| Differentiated Thyroid Carcino...Opens in new tab | Differentiated Thyroid Carcinoma | Complete | PH0021-000 | ||||||
| axicabtagene ciloleucelOpens in new tab | Yescarta | axicabtagene ciloleucel | Diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL) | Reimburse with clinical criteria and/or conditions | Complete | PG0293-000 | |||
| durvalumabOpens in new tab | Imfinzi | durvalumab | Biliary tract cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0296-000 | |||
| pembrolizumabOpens in new tab | Keytruda | pembrolizumab | Advanced endometrial cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0280-000 | |||
| dupilumabOpens in new tab | Dupixent | dupilumab | Asthma | Reimburse with clinical criteria and/or conditions | Complete | SR0745-000 | |||
| anifrolumabOpens in new tab | Saphnelo | anifrolumab | Systemic lupus erythematosus | Reimburse with clinical criteria and/or conditions | Complete | SR0717-000 | |||
| deferiproneOpens in new tab | Ferriprox | deferiprone | Transfusional iron overload | Reimburse with clinical criteria and/or conditions | Complete | SR0741-000 | |||
| belimumabOpens in new tab | Benlysta | belimumab | Lupus nephritis | Reimburse with clinical criteria and/or conditions | Complete | SR0746-000 | |||
| brolucizumabOpens in new tab | Beovu | brolucizumab | Diabetic macular edema | Reimburse with clinical criteria and/or conditions | Complete | SR0747-000 | |||
| dupilumabOpens in new tab | Dupixent | dupilumab | atopic dermatitis | Reimburse with clinical criteria and/or conditions | Complete | SF0754-000 | |||
| HER2 Positive Metastatic Breas...Opens in new tab | HER2 Positive Metastatic Breast Cancer | Complete | PH0016-000 | ||||||
| Renal Cell CarcinomaOpens in new tab | Renal Cell Carcinoma | Complete | PH0019-000 | ||||||
| Metastatic Urothelial Carcinom...Opens in new tab | Metastatic Urothelial Carcinoma | Complete | PH0017-000 | ||||||
| lemborexantOpens in new tab | Dayvigo | lemborexant | Insomnia | Do not reimburse | Complete | SR0716-000 | |||
| pembrolizumabOpens in new tab | Keytruda | pembrolizumab | Triple-negative breast cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0295-000 | |||
| darolutamideOpens in new tab | Nubeqa | darolutamide | Metastatic castration-sensitive prostate cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0294-000 | |||
| tebentafuspOpens in new tab | Kimmtrak | tebentafusp | unresectable or metastatic uveal melanoma | Reimburse with clinical criteria and/or conditions | Complete | PC0290-000 | |||
| edaravoneOpens in new tab | Radicava | edaravone | Amyotrophic lateral sclerosis | Reimburse with clinical criteria and/or conditions | Complete | SR0727-000 | |||
| lurbinectedinOpens in new tab | Zepzelca | lurbinectedin | metastatic small cell lung cancer (SCLC) | Do not reimburse | Complete | PC0281-000 | |||
| eptinezumabOpens in new tab | Vyepti | eptinezumab | Migraine | Reimburse with clinical criteria and/or conditions | Complete | SR0743-000 | |||
| dexamethasone intravitreal imp...Opens in new tab | Ozurdex | dexamethasone intravitreal implant | Diabetic macular edema | Do not reimburse | Complete | SR0739-000 | |||
| pitolisant hydrochlorideOpens in new tab | Wakix | pitolisant hydrochloride | Narcolepsy | Do not reimburse | Complete | SR0715-000 |
Health Technology Review
Displaying 201 - 225 of 602
Please scroll or swipe to view the full content.
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 1 - 25 of 25
View All Reports
Displaying 201 - 225 of 2142
Please scroll or swipe to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|---|
| Colorectal cancerOpens in new tab | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0062-000 | |||
| erdafitinibOpens in new tab | Reimbursement Review | Active | PC0375-000 | ||||
| leuprolide mesylateOpens in new tab | Reimbursement Review | Active | PC0370-000 | ||||
| Chronic lymphocytic leukemia (CLL)Opens in new tab | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0063-000 | |||
| Health System Readiness for Disease-Modifying Therapies for Alzheimer's DiseaseOpens in new tab | Health Technology Review | Active | CM0003-000 | ||||
| durvalumab, olaparib, carboplatin, paclitaxelOpens in new tab | Reimbursement Review | Withdrawn | PC0366-001 | ||||
| pembrolizumab Opens in new tab | Reimbursement Review | Complete | PC0356-000 | ||||
| osimertinibOpens in new tab | Reimbursement Review | Complete | PC0336-000 | ||||
| Utilization of Drugs in Patients With Major Neurocognitive DisorderOpens in new tab | Health Technology Review | Technology Review | In Progress | HC0099-000 | |||
| Trends in hydromorphone prescribing in Canada from 2018 to 2024Opens in new tab | Health Technology Review | Technology Review | In Progress | HC0096-000 | |||
| capivasertibOpens in new tab | Reimbursement Review | Complete | PC0341-000 | ||||
| dostarlimabOpens in new tab | Reimbursement Review | Complete | PC0325-000 | ||||
| sacituzumab govitecanOpens in new tab | Reimbursement Review | Complete | PC0323-000 | ||||
| sotorasib Opens in new tab | Reimbursement Review | Complete | PC0300-000 | ||||
| nivolumabOpens in new tab | Reimbursement Review | Complete | PC0303-000 | ||||
| darolutamideOpens in new tab | Reimbursement Review | Complete | PC0294-000 | ||||
| pembrolizumab Opens in new tab | Reimbursement Review | Complete | PC0292-000 | ||||
| tebentafusp Opens in new tab | Reimbursement Review | Complete | PC0290-000 | ||||
| atezolizumabOpens in new tab | Reimbursement Review | Complete | PC0269-000 | ||||
| pembrolizumabOpens in new tab | Reimbursement Review | Complete | PC0273-000 | ||||
| ripretinib Opens in new tab | Reimbursement Review | Complete | PC0265-000 | ||||
| nivolumabOpens in new tab | Reimbursement Review | Complete | PC0259-000 | ||||
| tepotinib Opens in new tab | Reimbursement Review | Complete | PC0255-000 | ||||
| daratumumab Opens in new tab | Reimbursement Review | Complete | PC0257-000 | ||||
| sacituzumab govitecan Opens in new tab | Reimbursement Review | Complete | PC0254-000 |
Provisional Funding Algorithm
Displaying 76 - 81 of 81